Friday, October 25, 2013

CytRx (CYTR) to Present Global Phase 2b Clinical Data for Aldoxorubicin at Annual Connective Tissue Oncology Society Meeting

Oncology-focused biopharmaceutical research and development company CytRx Corporation announced it will present additional preliminary data from its Phase 2b clinical trial – demonstrating aldoxorubicin’s potential advantage over doxorubicin in treating soft tissue sarcoma (STS) – at the 18th Annual Connective Tissue Oncology Society (CTOS) Meeting, taking place Thursday, Oct. 31 in the Sheraton New York Times Square Hotel.

CytRx previously reported that patients in the trial who were treated with aldoxorubicin had an overall response rate (ORR) of 22 percent, as opposed to those administered the widely used chemotherapeutic agent doxorubicin, who had an ORR of 0 percent. CytRx plans to report topline data for the global Phase 2 clinical trial in December of this year.

CTOS attracts sarcoma treatment leaders from around the world, making it an ideal forum for CytRx to spread awareness of this data and to also acquaint oncologists with its Phase 3 study in patients with relapsed or refractory soft tissue sarcomas. There have been relatively few discoveries of new sarcoma treatments, particularly when compared with treatments for breast or prostate cancer, but these preliminary clinical results have fueled CytRx’s optimism that aldoxorubicin can fill an important medical need in patients with advanced soft tissue sarcoma.

Soft tissue sarcoma is a cancer that occurs in muscle, fat, blood vessels, tendons, fibrous tissues and connective tissue. There are more than 30 types of STS, and it can arise anywhere in the body at any age. According to the American Cancer Society, more than 10,500 new cases are diagnosed in the U.S. each year.

In addition to its Phase 2b trial for STS, CytRx has received acceptance from the FDA for a protocol to conduct a Phase 2 clinical trial with aldoxorubicin in glioblastoma, a deadly brain cancer that is difficult to treat. The company also plans to conduct a Phase 2 clinical trial in HIV-related Kaposi’s sarcoma.

For more information, visit www.cytrx.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

No comments: